In March, when affluent Britain was leading the world in vaccine coverage, and almost half of its population had gotten a shot, the organization responsible for ensuring equitable worldwide access to COVID-19 vaccinations granted the country more than half a million dosages from its supply of the vaccine.
According to the documents, according to publicly accessible papers outlining COVAX’s allocations, Botswana, which had not yet begun its immunization campaign, was allocated 20,000 doses from the same lot of millions of Pfizer mRNA vaccines as the rest of the world.
The Global Vaccines Project Will Revise Its Rules
Other poorer countries, with at best nascent immunization campaigns, likewise got fewer doses than the United Kingdom. Rwanda and Togo each received about 100,000 doses, with Libya receiving approximately 55,000.
In this case, the approach employed by COVAX, a program co-led by the World Health Organization, the Coalition for Epidemic Preparedness Innovations (CEPI), and the Global Alliance for Vaccines and Immunization, served as the driving force behind the distribution (Gavi).
Since January, it has mainly distributed dosages proportionately among its members in accordance with population size, regardless of whether or not they have had vaccinations.
As a result, some wealthy countries, which already had a large number of vaccinations as a result of other agreements with pharmaceutical companies, were eligible to receive COVAX doses with countries that had no vaccines at all.
COVAX plans to overhaul the see how six months after the initial implementation to ensure that it considers the proportion of a nation’s people which has been immunized, including shots bought separately from drugmakers, as per an internal Gavi report obtained by Reuters and reviewed by Reuters.
In the paper, it is said that the idea would be addressed at the Gavi board meeting and that the move may be implemented as early as the fourth half of this year.
The COVID-19 pandemic has posed an almost innovative change. Big, respected organizations like the World Health Organization and the United States CDC and Prevention have struggled to keep up with and adjust their strategies as new information comes in.
A high-ranking WHO and COVAX official, when asked why overall vaccine coverage had not been used earlier as an indicator of progress, responded that the allotment terms could not be altered without the permission of COVAX‘s and over 140 member nations. However, he did not comment on the attempt to reach a consensus.
He went on to say that concrete evidence on the effectiveness of vaccinations was now available, which reinforced the argument for a shift in policy. According to the expert, it is only in the past couple of months that “the difference between cases and fatalities as a consequence of vaccine coverage” has become apparent.
Overall, the United Kingdom will be a net contributor in terms of money and vaccinations. It has spent 71 million pounds in COVAX, which theoretically enables it to purchase up to 27 million doses. Additionally, it started giving up to nine million injections this summer, some of which were administered via COVAX.